Research - 7investing 7investing
Stock Tips Mobile Menu Dropdown Icon

Stock Market Research

Better investing begins with better research.

7investing Stock Market Research

Being your own investor doesn’t mean you have to go it alone. Improve your investing insights with the stock market research of the 7investing lead advisors. 

Our team dives deeper, going beyond the tickers and trends to provide you with the credible, actionable information you need to make the right moves and achieve your stock market investing goals. Read on to stay up to date with the latest 7investing research articles, podcasts, videos, and updates on your favorite companies. 


Rocket Lab's Stock is Worth $22 and has 453% Upside. Here's Why.: Rocket Lab

Mar 21, 2024

My Discounted Cash Flow analysis calculates that Rocket Lab's stock is worth $22.35 per share. That represents 453% upside from today's current price, making it one of the stock market's most undervalued and intriguing opportunities.

Featured Articles



Mar 14, 2024


Contest Matchup #3: The Trade Desk vs Palantir

Mar 12, 2024

Two smart companies who are embracing AI to become even smarter. Which will be the wiser investment for 2024?


Contest Matchup #2: Uber vs Rocket Lab

Mar 6, 2024

In our second of seven Stockpicking Challenge matchups, the mover of people squares up against the mover of satellites.

Recent Research


Introducing 7investing’s Stockpicking Competition!

Mar 4, 2024

Enter to win a $1,000 Amazon gift card and a free year of 7investing.


Is Tech Hiring Picking Back Up?

Feb 15, 2024

Encouraging data shows that (some) tech companies are looking for new engineering talent.


AI is Bringing Synthetic Biology Back to Life

Feb 6, 2024

New AI tools could supercharge the emerging field of generative biology. The therapeutics segment might be a natural fit.


Investing in the Cloud: Mission-Critical, Land-and-Expand, and Sustainable Growth

Jan 22, 2024

Guest contributor Anand Khatri from StocksCurrent describes how investors should approach the cloud computing industry.


2024 NFL Mock Draft 1.0

Jan 21, 2024

7investing CEO Simon Erickson shares his mock draft outlook of what NFL fans should expect this April.


Why Seres Therapeutics is My Best Buy in January

Jan 17, 2024

The market's first microbiome company is getting a good reception to its first commercially-approved drug.


ZoomInfo: Time for a Turnaround?

Jan 11, 2024

The sales platform looks primed for a turnaround.


How Do Renewable Energy Projects Get Evaluated?

Dec 28, 2023

7investing CEO Simon Erickson shares a primer on how renewable projects tend to be evaluated by larger energy companies.


TaskUs is “Dirt Cheap”; My Review of its Q3 2023…

Dec 11, 2023

7investing advisor Anirban Mahanti shares his thoughts about TaskUs' most recent quarterly results.


Is Seres Therapeutics Preparing To Be Acquired?

Nov 3, 2023

Seres Therapeutics announced great initial sales data but also a company restructuring. Is it preparing for an upcoming acquisition?